-
Endpoints News2 weeks ago
FDA approves Novo Nordisk’s once-weekly insulin
The FDA finally greenlit Novo Nordisk’s once-weekly insulin for type 2 diabetes, making it the first US-approved longer-acting alternative to daily basal treatment for this indication....
-
Uncategorized2 weeks ago
Webinar: Aligning With the FDA on a Regulatory Pathway To Avoid Decision Day Surprises
Watch this critical discussion on how regulators and biotech companies can bridge the expectation gap during the regulatory review process to ensure novel therapies reach patients...
-
STAT News – Biotech2 weeks agoSTAT+: Pharmalittle: We’re reading about Novo Nordisk boosting consumer focus, FDA approving a gene therapy, and more
And so, another working week will soon draw to a close. Not a moment too soon, yes? This is, you may recall, our treasured signal to...
-
Uncategorized2 weeks agoThis week in Drug Discovery (23 – 27 March)
News round-up for 23 – 27 March February by Bruno Quinney, Content Team at DDW. This week, obesity could be treated in other ways than through drugs suppressing appetite. Elsewhere, prostate cancer...
-
Uncategorized2 weeks ago
After Speaking out of Turn, Malone Steps Down From Vaccine Committee
Former ACIP vice chair Robert Malone claimed that Andrew Nixon, spokesperson for the Department of Health and Human Services, “trashed” him with the media, adding that...
-
BioPharma Dive – AI / Data2 weeks ago
Rocket gene therapy cleared by FDA for rare immune disorder
Though the therapy, Kresladi, isn’t seen as a big seller, its clearance is a step forward for a company that’s lost most of its value since...
-
Endpoints News2 weeks ago
AstraZeneca’s in vivo CAR-T led to early responses, but one death in China trial
New clinical trial data on the in vivo CAR-T therapy that AstraZeneca acquired last year suggest that while the experimental treatment can curb multiple myeloma in...
-
Uncategorized2 weeks agoBeam reports positive data for genetic disease treatment
Biotechnology company Beam Therapeutics has reported encouraging data for its treatment for the genetic disease Alpha-1 Antitrypsin Deficiency (AATD). Beam announced BEAM-302, a liver-targeting lipid-nanoparticle (LNP) formulation...
-
Uncategorized2 weeks ago
Rocket’s Gene Therapy Wins FDA Greenlight, Clearing Way for Future Products
While the accelerated approval unlocks only a small market opportunity for Rocket Pharmaceuticals, it will give the biotech a chance to prepare for future product launches,...
-
Uncategorized2 weeks ago
Novartis Keeps Deals Coming With $2B Excellergy Takeover
The Excellergy acquisition will complement Novartis’ existing allergy profile, anchored by the IgE blocker Xolair that in February 2024 was approved to treat food allergies in...
Terns rebuffed a higher bid before selling to Merck
